After acquiring 23andMe, Regeneron Pharmaceuticals has said it will protect user data as it uses DNA data for drug development.

Regeneron is buying 23andMe for $256M in bankruptcy, gaining access to DNA data from 15 million users to aid drug research.

On Monday, Regeneron Pharmaceuticals announced that it would acquire most of 23andMe's assets for $256 million. According to Regeneron Pharmaceuticals, the acquisition includes 23andMe's Personal Genome Service, Total Health and Research Services business lines, and the trove of customers' DNA samples and genetic data.